The CAR-γδT cell therapy QH104, independently developed by a Chinese team, has demonstrated a 100% disease control rate in patients with relapsed glioblastoma

**The CAR-γδT cell therapy QH104, independently developed by a Chinese team, has demonstrated a 100% disease control rate in patients with relapsed glioblastoma.**

#glioblastoma #CARγδT #QH104 #γδT #B7H3 #rGBM #CARgammaT

glioblastoma

A groundbreaking CAR-γδT cell therapy, QH104, developed by a Chinese team, is gaining attention in the global medical community for its potential in treating relapsed glioblastoma (rGBM). Targeting B7H3, QH104 is an allogeneic, off-the-shelf therapy with the promise of higher accessibility due to lower production costs compared to autologous cell therapies.

One of the unique strengths of γδT cells is their ability to recognize antigens without MHC restriction, reducing the risk of graft-versus-host disease (GvHD) and making them an ideal candidate for universal cell therapy.

The Phase I clinical trial, a single-center, dose-escalation study, tested QH104 on B7H3-positive rGBM patients who had already completed standard treatments. These patients had a Karnofsky Performance Status (KPS) score of 60 or higher and a minimum life expectancy of three months. The trial followed a “3+3” dose escalation model, with patients receiving intrathecal injections of QH104 once per month.

As of March 30, 2024, seven high-grade rGBM patients (five males, two females, median age 60) had undergone at least one dose of QH104 and were monitored for an average of 6.5 months. The therapy showed an excellent safety profile, with no dose-limiting toxicities. Although minor side effects like fever and headaches were observed, no severe cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or GvHD occurred. Importantly, QH104 exhibited remarkable efficacy, with an objective response rate (ORR) of 42.9% and a disease control rate (DCR) of 100%, ensuring that all patients saw some level of disease stabilization.

Even more encouraging, 30 days post-treatment, the infused cells were still detectable in patients, indicating the therapy’s persistence. Additionally, a positive correlation between B7H3 expression and clinical outcomes suggests that QH104 could be further personalized to optimize patient selection and treatment protocols in the future.

This pioneering approach marks a significant step forward in CAR-γδT therapy, offering hope for patients with relapsed glioblastoma.

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #Immunotherapy #MedicalBreakthrough #CellTherapy #HealthcareInnovation